Charles River Laboratories International, Inc. (CRL)’s Chairman & CEO James Foster Unloaded 3810 shares of the Company; Arista Networks, Inc. (ANET) Had 17 Analysts Last Week

The Chairman & CEO of Charles River Laboratories International Inc, James Foster is in the stock market news today. It was announced in a report filled by James Foster and submitted to the U.S. SEC on February 27, 2018, he unloaded 3,810 shares from the Massachusetts-based company having a total value of $410,199 US Dollars. James Foster’s shares average price was $107.7. This is not his first insider trade, in the last month, he sold another 15,014 shares worth $1,612,419 USD. Presently, he holds a total of 321,707 shares or 0.68% of the Company’s total market capitalization.

Among 35 analysts covering Arista Networks (NYSE:ANET), 17 have Buy rating, 0 Sell and 18 Hold. Therefore 49% are positive. Arista Networks had 122 analyst reports since July 29, 2015 according to SRatingsIntel. Jefferies maintained Arista Networks, Inc. (NYSE:ANET) on Friday, November 3 with “Hold” rating. Goldman Sachs initiated Arista Networks, Inc. (NYSE:ANET) on Tuesday, February 6 with “Buy” rating. The rating was maintained by Cowen & Co on Thursday, October 19 with “Buy”. The firm has “Neutral” rating given on Monday, March 27 by Goldman Sachs. The company was maintained on Friday, August 4 by RBC Capital Markets. The rating was maintained by BMO Capital Markets on Thursday, June 15 with “Buy”. The company was downgraded on Monday, December 5 by Morgan Stanley. Needham maintained the stock with “Buy” rating in Tuesday, September 12 report. Nomura maintained it with “Neutral” rating and $250 target in Tuesday, February 20 report. The stock has “Buy” rating by KeyBanc Capital Markets on Thursday, January 18. See Arista Networks, Inc. (NYSE:ANET) latest ratings:

21/02/2018 Broker: BMO Capital Markets Rating: Hold New Target: $270.0 Maintain
20/02/2018 Broker: Nomura Old Rating: Neutral New Rating: Neutral Old Target: $185 New Target: $250 Maintain
16/02/2018 Broker: Jefferies Rating: Hold New Target: $224.0 Maintain
16/02/2018 Broker: Nomura Rating: Hold New Target: $250.0 Maintain
16/02/2018 Broker: KeyBanc Capital Markets Rating: Buy New Target: $295.0 Maintain
16/02/2018 Broker: Piper Jaffray Rating: Hold New Target: $268.0 Maintain
16/02/2018 Broker: Cowen & Co Rating: Buy New Target: $292.0 Maintain
16/02/2018 Broker: M Partners Rating: Hold New Target: $285.0
16/02/2018 Broker: Gabelli Old Rating: Buy New Rating: Hold Downgrade
06/02/2018 Broker: Goldman Sachs Rating: Buy New Target: $320.0 Initiate

Analysts await Charles River Laboratories International, Inc. (NYSE:CRL) to report earnings on May, 9. They expect $1.25 earnings per share, down 3.10% or $0.04 from last year’s $1.29 per share. CRL’s profit will be $59.28 million for 20.99 P/E if the $1.25 EPS becomes a reality. After $1.40 actual earnings per share reported by Charles River Laboratories International, Inc. for the previous quarter, Wall Street now forecasts -10.71% negative EPS growth.

Among 17 analysts covering Charles River Laboratories (NYSE:CRL), 8 have Buy rating, 1 Sell and 8 Hold. Therefore 47% are positive. Charles River Laboratories has $124 highest and $65 lowest target. $106’s average target is 1.01% above currents $104.94 stock price. Charles River Laboratories had 45 analyst reports since August 3, 2015 according to SRatingsIntel. Deutsche Bank maintained the stock with “Hold” rating in Friday, July 31 report. As per Wednesday, November 30, the company rating was upgraded by Barclays Capital. The stock of Charles River Laboratories International, Inc. (NYSE:CRL) earned “Buy” rating by Robert W. Baird on Tuesday, February 13. The firm earned “Buy” rating on Thursday, June 29 by Jefferies. Jefferies maintained Charles River Laboratories International, Inc. (NYSE:CRL) on Friday, January 8 with “Buy” rating. Credit Suisse reinitiated Charles River Laboratories International, Inc. (NYSE:CRL) on Friday, August 14 with “Neutral” rating. On Friday, November 10 the stock rating was maintained by Bank of America with “Buy”. The firm has “Neutral” rating by Goldman Sachs given on Friday, December 16. The stock of Charles River Laboratories International, Inc. (NYSE:CRL) earned “Buy” rating by Jefferies on Monday, October 9. The firm has “Hold” rating given on Monday, January 22 by SunTrust.

Since September 5, 2017, it had 0 insider buys, and 14 sales for $7.10 million activity. 24,759 shares were sold by JOHST DAVID P, worth $2.72 million. Another trade for 319 shares valued at $34,620 was made by Smith David Ross on Monday, February 26. Shares for $312,172 were sold by CHUBB STEPHEN D on Thursday, February 15. Another trade for 6,165 shares valued at $678,150 was made by Molho Davide on Thursday, October 5. 2,320 Charles River Laboratories International, Inc. (NYSE:CRL) shares with value of $250,741 were sold by Barbo William D. $4,945 worth of Charles River Laboratories International, Inc. (NYSE:CRL) was sold by FOSTER JAMES C.

Investors sentiment increased to 1.46 in 2017 Q3. Its up 0.09, from 1.37 in 2017Q2. It increased, as 18 investors sold Charles River Laboratories International, Inc. shares while 92 reduced holdings. 55 funds opened positions while 106 raised stakes. 44.95 million shares or 0.15% less from 45.02 million shares in 2017Q2 were reported. Cadence Ltd Liability Corp owns 17,500 shares for 0.12% of their portfolio. Credit Agricole S A holds 6,064 shares or 0% of its portfolio. Hbk Lp holds 0% in Charles River Laboratories International, Inc. (NYSE:CRL) or 3,892 shares. Weaver C Barksdale Associate Inc reported 92 shares or 0.01% of all its holdings. Private Trust Na owns 4,326 shares or 0.1% of their US portfolio. Arizona State Retirement Systems has invested 0.03% in Charles River Laboratories International, Inc. (NYSE:CRL). Rockefeller Finance Incorporated reported 0% in Charles River Laboratories International, Inc. (NYSE:CRL). Prudential Financial holds 0.08% or 433,670 shares. Tekla Capital Limited Liability Company reported 0.49% in Charles River Laboratories International, Inc. (NYSE:CRL). Oakbrook Invests Ltd Liability owns 4,517 shares. California-based Lpl Limited Liability Company has invested 0% in Charles River Laboratories International, Inc. (NYSE:CRL). 40,000 are held by State Of Tennessee Treasury Department. 131,661 were accumulated by Amundi Pioneer Asset Mngmt. Parametric Associates Limited Com holds 104,255 shares or 0.01% of its portfolio. Manufacturers Life Insurance The reported 69,749 shares.

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and development services worldwide. The company has market cap of $4.98 billion. It operates through three divisions: Research Models and Services , Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). It has a 41.36 P/E ratio. The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers.

The stock decreased 1.57% or $1.67 during the last trading session, reaching $104.94. About 460,621 shares traded or 14.93% up from the average. Charles River Laboratories International, Inc. (NYSE:CRL) has risen 7.06% since March 2, 2017 and is uptrending. It has underperformed by 9.64% the S&P500.